Efficacy of Hepatitis B vaccine in those who lost Hepatitis B surface antigen during follow-up: Efficacy of HBV vaccine in those who lost HBsAg

Hassan Taheri, Mohammad Reza Hasanjani Roushan, Mohammad Jafar Soleimani Amiri, Mohammad Pouralijan, Ali Bijani, Hassan Taheri, Mohammad Reza Hasanjani Roushan, Mohammad Jafar Soleimani Amiri, Mohammad Pouralijan, Ali Bijani

Abstract

Background: The level of HBsAg in some chronic hepatitis B virus (HBV)-infected individuals may decline over time so that it is not detectable in serum.

Objective: To assess the efficacy of HBV vaccine in those who lost their HBsAg without seroconverssion to anti-HBs antibody.

Patients and methods: From April 1993 to December 2008, of 1603 chronic HBV-infected individuals, 34 (22 men and 12 women) became HBsAg-negative in follow-up visits, with no detectable anti-HBs antibody and HBV DNA in their sera. They received HBV vaccination at 0, 1 and 6 months (case group). Fifty-two subjects (30 men and 22 women) who were negative for HBsAg, anti-HBs and anti-HBc antibody, received HBV vaccination according to the said schedule (control group). Anti-HBs antibody was assessed one month after the last dose of vaccination in the both groups.

Results: The mean±SD age of the case and control groups was 38±12.7 and 33.4 ± 8.6 years, respectively (p = 0.07). The sex distribution between these two groups were similar (p = 0.652). The mean ± SD years of follow-up for the case group was 7.6 ± 4.5 years. Anti-HBs antibody level ≥ 10 IU/L was found in 8 (24%) subjects in the case group and in 45 (87%) in the control group (p < 0.001). The mean±SD anti-HBs antibody level in the case group was 68 ± 32.66 and in the control group 344.6 ± 38.9 IU/L (p < 0.001).

Conclusions: We found that nearly 24% of chronic HBsAg-positive subjects who lost their HBsAg responded to HBV and the remaining cases need to be followed for occult HBV infection.

Keywords: Chronic hepatitis B; Follow-up study; HBsAg; Hepatitis B vaccine; Hepatitis B virus.

References

    1. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev. 1999;12(2):351–66.
    1. Koziel MJ, Siddiqui A. Hepatitis B virus and hepatitis B virus. In: Mandell GL, Bennett JE, Dolin E, editors. Principles and Practice of Infectious diseases. Philadelphia: Churchill Livingstone; 2005. pp. 1864–90.
    1. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;135(9):759–68.
    1. Bréchot C, Degos F, Lugassy C, Thiers V, Zafrani S, Franco D, Bismuth H, Trépo C, Benhamou JP, Wands J. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med. 1985;312(5):270–6.
    1. Altindiş M, Uslan I, Cetinkaya Z, Yüksel S, Ciftçi IH, Demirtürk N, Ozdemir M, Arslan F, Aktepe OC. Investigation of hemodialysis patients in terms of the presence of occult hepatitis B. Mikrobiyol Bul. 2007;41(2):227–33.
    1. Jain P, Nijhawan S. Occult hepatitis C virus infection is more common than hepatitis B infection in maintenance hemodialysis patients. World J Gastroenterol. 2008;14(14):2288–9.
    1. Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, Gutkin A, Bernstein K, Giulivi A, Osiowy C. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004;40(5):1072–7.
    1. Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, Keles H. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail. 2006;28(8):729–35.
    1. Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology. 1988;8(4):766–70.
    1. Koh HJ, Kim SD, Choi JH, Kim SR, Lee JS. [A study of immune response to hepatitis B vaccine & HBV DNA in isolated anti-HBc positive subjects] J Prev Med Public Health. 2005;38(2):170–4.
    1. Ural O, Findik D. The response of isolated anti-HBc positive subjects to recombinant hepatitis B vaccine. J Infect. 2001;43(3):187–90.
    1. Zuckerman JN, Zuckerman AJ. Current topics in hepatitis B. J Infect. 2000;41(2):130–6.
    1. Chan CY, Lee SD, Tsai YT, Lo KJ. Hepatitis B vaccination alone is not adequate for the categorizing of adult subjects with isolated anti-HBc. J Gastroenterol Hepatol. 1995;10(2):192–7.
    1. Coz Yataco A, Lozano Miranda A, Samalvides Cuba F, Antunez de Mayolo Ramis E. Significance of the. Rev Gastroenterol Peru. 2005;25(3):254–8.
    1. Draelos M, Morgan T, Schifman RB, Sampliner RE. Significance of isolated antibody to hepatitis B core antigen determined by immune response to hepatitis B vaccination. JAMA. 1987;258(9):1193–5.
    1. Sunbul M, Leblebicioglu H, Esen S, Eroglu C, Barut S. Response to hepatitis B vaccine in HBsAg/anti-HBs negative and anti-HBc positive subjects. Scand J Infect Dis. 2000;32(3):315–6.
    1. Tseng KC, Lei HY, Cheng PN, Young KC, Jen CM, Wu CH, Chang TT. Immune response to hepatitis B vaccine of subjects with isolated antibody to hepatitis B core antigen. Hepatogastroenterology. 2003;50(53):1474–7.
    1. Lai CL, Lau JY, Yeoh EK, Chang WK, Lin HJ. Significance of isolated anti-HBc seropositivity by ELISA: implications and the role of radioimmunoassay. J Med Virol. 1992;36(3):180–3.
    1. Kabir A, Keshvari M, Kashani AH, Alavian SM. Predicting response to HBV vaccination in people with positive anti-HBc but negative HBsAg and anti-HBs. Hum Vaccin. 2008;4(5):379–83.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner